Eprenetapopt Withdrawn Phase 2 Trials for Recurrent Mantle Cell Lymphoma / Refractory Mantle Cell Lymphoma Treatment
| Indications | Status | Purpose | Phase |
|---|---|---|---|
| Withdrawn | Treatment | 2 |
| clinicaltrials.gov Identifier | Title | Drugs |
|---|---|---|
| NCT04990778 | Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma |